Pembrolizumab,Axitinib,Sunitinib
Merck,Pfizer
['pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'axitinib']
pembrolizumab/axitinib efficacy in ccrcc sustained at 5-year follow-up #asco23 #urology #urologist #kidneycancer
The Leading News Source for Urologists - https://t.co/hDKngB4IyE
Expert clinical analysis. Practice advice. Policy perspectives.